B
TGTX icon

Braidwell’s TG Therapeutics TGTX Stock Holding History

Braidwell’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-358,800
Closed -$11.9M – 108
2026
Q1 		$11.9M Buy
+358,800
New +$10.7M 0.4% 69

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Braidwell's TGTX Position: Q2 2026 in Review

Braidwell sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 358,800 shares — an estimated $11.9M sold.

Braidwell first reported a position in TGTX in Q1 2026 and held it in 1 quarter. The position peaked at $11.9M in Q1 2026. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Braidwell reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Braidwell sold 358,800 TG Therapeutics shares in Q2 2026, an estimated $11.9M.
  • Braidwell first reported a position in TG Therapeutics in Q1 2026 and held it in 1 quarter.
  • Braidwell's TG Therapeutics position peaked at $11.9M in Q1 2026.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.